These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30125290)

  • 1. A 'Comprehensive Visual Rating Scale' for predicting progression to dementia in patients with mild cognitive impairment.
    Jang JW; Park JH; Kim S; Park YH; Pyun JM; Lim JS; Kim Y; Youn YC; Kim S;
    PLoS One; 2018; 13(8):e0201852. PubMed ID: 30125290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
    Pyun JM; Park YH; Kim HR; Suh J; Kang MJ; Kim BJ; Youn YC; Jang JW; Kim S;
    Alzheimers Res Ther; 2017 Dec; 9(1):99. PubMed ID: 29246250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Visual Rating Scale for Predicting Progression from Mild Cognitive Impairment to Dementia in Patients with Alzheimer's Pathology or Suspected Non-Alzheimer's Pathology.
    Park SW; Kim S; Park J; Jang JW; Kim S
    Dement Neurocogn Disord; 2020 Dec; 19(4):129-139. PubMed ID: 33377666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Visual Rating Scale on Magnetic Resonance Imaging: Application to Prodromal Alzheimer Disease.
    Chung JK; Jang JW
    Ann Geriatr Med Res; 2021 Mar; 25(1):39-44. PubMed ID: 33715339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive visual rating scale of brain magnetic resonance imaging: application in elderly subjects with Alzheimer's disease, mild cognitive impairment, and normal cognition.
    Jang JW; Park SY; Park YH; Baek MJ; Lim JS; Youn YC; Kim S
    J Alzheimers Dis; 2015; 44(3):1023-34. PubMed ID: 25380589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
    Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
    Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients.
    Kim HR; Park YH; Jang JW; Park SY; Wang MJ; Baek MJ; Kim BJ; Ahn S; Kim S
    J Alzheimers Dis; 2017; 55(1):137-146. PubMed ID: 27636842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment.
    Moon B; Kim S; Park YH; Lim JS; Youn YC; Kim S; Jang JW;
    J Alzheimers Dis; 2017; 58(4):1255-1264. PubMed ID: 28550264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting progression to dementia with "comprehensive visual rating scale" and machine learning algorithms.
    Park C; Jang JW; Joo G; Kim Y; Kim S; Byeon G; Park SW; Kasani PH; Yum S; Pyun JM; Park YH; Lim JS; Youn YC; Choi HS; Park C; Im H; Kim S
    Front Neurol; 2022; 13():906257. PubMed ID: 36071894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals.
    van der Kall LM; Truong T; Burnham SC; Doré V; Mulligan RS; Bozinovski S; Lamb F; Bourgeat P; Fripp J; Schultz S; Lim YY; Laws SM; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Maruff P; Masters CL; Villemagne VL; Rowe CC
    Neurology; 2021 Feb; 96(5):e662-e670. PubMed ID: 33184233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative.
    Spencer BE; Jennings RG; Brewer JB;
    J Alzheimers Dis; 2019; 68(4):1549-1559. PubMed ID: 30958366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
    Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
    J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.